110020 — Jeonjin Bio Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩31bn
- KR₩31bn
- KR₩16bn
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,949 | 3,867 | 3,214 | 7,794 | 15,681 |
Cost of Revenue | |||||
Gross Profit | 2,087 | 2,216 | 1,363 | 2,006 | 4,870 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5,907 | 6,032 | 6,244 | 10,847 | 17,489 |
Operating Profit | -1,958 | -2,166 | -3,030 | -3,053 | -1,808 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,462 | -3,418 | -2,108 | -3,113 | -6,440 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,462 | -3,418 | -2,108 | -3,113 | -6,440 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,462 | -3,418 | -2,108 | -3,113 | -6,440 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -1,462 | -3,418 | -2,108 | -3,113 | -6,440 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -284 | -639 | -340 | -485 | -808 |
Dividends per Share |